chronic hepatitis

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to chronic hepatitis: Chronic Hepatitis B

chron·ic hep·a·ti·tis

any of several types of hepatitis persisting for longer than 6 months, often progressing to cirrhosis.

chronic hepatitis

Etymology: Gk, chronos, time, hēpar, liver, itis, inflammation
a state in which symptoms of hepatitis continue for several months and may increase in severity. In some cases of hepatitis B, the patient may become a lifelong carrier of the antigen and may show prolonged evidence of the infection. See also alcoholic hepatitis, anicteric hepatitis, cholestatic hepatitis, hepatitis, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E.

chronic hepatitis

Inflammation of the liver that does not improve within 6 months, excluding primary biliary cirrhosis, primary sclerosing cholangitis, alpha1 antitrypsin deficiency and Wilson’s disease. 

Autoimmune hepatitis, drug-induced hepatitis, HBV, HCV, HDV, chronic hepatitis of unknown origin (cryptogenic hepatitis).

Histologic clues for aetiology of chronic hepatitis
Viruses—Ground glass, fat, lymphoid aggregates, lymphocytosis, low grade.
Autoimmune—Plasma cells, rosetting, florid activity.
Drugs—Eosinophils, granulomas, mixed cellular reaction.

chronic hepatitis

Hepatology Inflammation of the liver that continues without improvement for ≥ 6 months. See Cirrhosis. Cf Acute hepatitis.

chron·ic hep·a·tit·is

(kronik hep-ă-tītis)
One of several types of liver disease persisting for longer than 6 months, often progressing to cirrhosis.

Chronic hepatitis

Long lasting inflammation of the liver due to viruses or other causes.

chronic hepatitis

carrier state of hepatitis B and C infections
References in periodicals archive ?
PEGASYS was studied in one of the largest clinical development programmes in chronic hepatitis B, which included three global studies in more than 1,500 patients from 19 countries.
At the briefing, Congressman Dent and Congressman Honda, along with government health agencies, third-party organizations, physicians and chronic hepatitis B patients, addressed Congressional leaders and aides about the importance of prioritizing chronic hepatitis B as a major health concern in the United States.
PEGASYS has been proven twice as effective as conventional interferon for the treatment of the most common form of chronic hepatitis B, hepatitis B e antigen (HBeAg) -positive chronic hepatitis B, in a multinational phase II trial.
PEGASYS was filed for the treatment of chronic hepatitis B simultaneously in Switzerland, the United States and the European Union in the summer of 2004, and approvals in the US and the EU are anticipated early in 2005.
15) A large cross-sectional study by Poynard et al (15) identified 3 categories of progression in patients with chronic hepatitis C: (1) rapid fibrosing, chronic hepatitis C that progresses to cirrhosis in less than 20 years; (2) intermediate fibrosing, chronic hepatitis C with a median progression of 30 years; and (3) slow fibrosing, chronic hepatitis C that will not progress for at least 50 years (Figure 3).
Pegasys, a new drug developed by Roche Pharmaceuticals to treat chronic hepatitis C, received approval this month from the U.
Chronic liver diseases often begin with the anatomic-clinical state of chronic hepatitis and can evolve to liver cirrhosis and hepatocarcinoma.
Definition - Chronic Hepatitis (CAH) is ongoing injury to the cells of the liver with inflammation which lasts for longer than six months.
In the other approach, based on growing evidence that the development and persistence of chronic hepatitis B infection may be caused by insufficient production of alpha interferon by white blood cells called lymphocytes, researchers use the interferon itself -- a small protein made by cells as a defense against viral infection and produced in quantity by laboratory recombinant techniques.
Food and Drug Administration (FDA) has granted marketing approval for Viread([R]) (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B virus (HBV).
May 4 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.

Full browser ?